Evotec EU Taxonomy disclosure

EU Taxonomy summary

10% of Evotec's revenues are EU Taxonomy eligible, with 0% also being Taxonomy aligned. 69% of Evotec's capital expenditures are EU Taxonomy eligible, with 0% also being Taxonomy aligned. Additionally, 5% of Evotec's operating expenses are EU Taxonomy eligible, with 0% also being Taxonomy aligned.

EU Taxonomy full disclosure

FY2023	Code	Value (EURth)	Proportion of total	CCM	CCA	WTR	PPC	CE	BIO	CCM DNSH	CCA DNSH	WTR DNSH	PPC DNSH	CE DNSH	BIO DNSH	Minimum safeguards	Previous year proportion	Category enabling activity	Category transitional activity
Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0%	0%	0%	0%	0%	0%	0%	N	N	N	N	N	N	N	0%
Of which enabling		0	0%	0%	0%	0%	0%	0%	0%
Of which transitional		0	0%	0%
7.1 = Construction of new buildings	CCM 7.1	0	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL
7.2 = Renovation of existing buildings	CCM 7.2	0	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL
1.1 = Manufacture of active pharmaceutical ingredients (API) or active substances	PPC 1.1	27,099	3%	N/EL	N/EL	N/EL	EL	N/EL	N/EL
1.2 = Manufacture of medicinal products	PPC 1.2	53,160	7%	N/EL	N/EL	N/EL	EL	N/EL	N/EL
Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		80,259	10%	0%	0%	0%	100%	0%	0%
A. Turnover of Taxonomy eligible activities (A.1+A.2)		80,260.123	10%
Turnover of Taxonomy-non-eligible activities		700,751	90%
Total (A+B)		781,011	100%

FY2023	Code	Value (EURth)	Proportion of total	CCM	CCA	WTR	PPC	CE	BIO	CCM DNSH	CCA DNSH	WTR DNSH	PPC DNSH	CE DNSH	BIO DNSH	Minimum safeguards	Previous year proportion	Category enabling activity	Category transitional activity
CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0%	0%	0%	0%	0%	0%	0%
Of which enabling		0	0%	0%	0%	0%	0%	0%	0%
Of which transitional		0	0%	0%
7.1 = Construction of new buildings	CCM 7.1	76	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL
7.2 = Renovation of existing buildings	CCM 7.2	10,723	5%	EL	N/EL	N/EL	N/EL	N/EL	N/EL
1.1 = Manufacture of active pharmaceutical ingredients (API) or active substances	PPC 1.1	2,949	1%	N/EL	N/EL	N/EL	EL	N/EL	N/EL
1.2 = Manufacture of medicinal products	PPC 1.2	132,479	63%	N/EL	N/EL	N/EL	EL	N/EL	N/EL
CapEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		146,227	69%	7.385%	0%	0%	92.615%	0%	0%
A. CapEx of Taxonomy eligible activities (A.1+A.2)		146,228	69%
CapEx of Taxonomy-non-eligible activities		64,727	31%
Total (A+B)		210,954	100%

FY2023	Code	Value (EURth)	Proportion of total	CCM	CCA	WTR	PPC	CE	BIO	CCM DNSH	CCA DNSH	WTR DNSH	PPC DNSH	CE DNSH	BIO DNSH	Minimum safeguards	Previous year proportion	Category enabling activity	Category transitional activity
OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)		0	0%	0%	0%	0%	0%	0%	0%
Of which enabling		0	0%	0%	0%	0%	0%	0%	0%
Of which transitional		0	0%	0%
7.1 = Construction of new buildings	CCM 7.1	0	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL
7.2 = Renovation of existing buildings	CCM 7.2	0	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL
1.1 = Manufacture of active pharmaceutical ingredients (API) or active substances	PPC 1.1	10,082	1%	N/EL	N/EL	N/EL	EL	N/EL	N/EL
1.2 = Manufacture of medicinal products	PPC 1.2	27,291	4%	N/EL	N/EL	N/EL	EL	N/EL	N/EL
OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		37,373	5%	0%	0%	0%	100%	0%	0%
A. OpEx of Taxonomy eligible activities (A.1+A.2)		37,373	5%
OpEx of Taxonomy-non-eligible activities		676,927	95%
Total (A+B)		714,300	100%

Evotec

EU Taxonomy summary

EU Taxonomy full disclosure

Revenues

Capital expenditures

Operating expenses